Ancora Heart

Focus: Ancora Heart is a early-stage medical device/biotechnology company focused on developing cardiac procedures for mitral valve regurgitation, a significant cardiovascular condition. Based in Santa Clara, CA, the company is positioned in the specialized cardiac intervention space.

Cardiovascular

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Open Jobs

About Ancora Heart

AI assessmentNot Hiring

No open roles listed right now. Follow Ancora Heart to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Left ventricular restoration

Heart Failure

N/A

Clinical Trials (1)

NCT03183895Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study

N/A

Help build intelligence for Ancora Heart

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a focused company targeting a large unmet need in cardiac surgery with growing prevalence of mitral valve disease
Specialized focus on high-value cardiovascular procedures positions the company in a premium market segment with potential for significant clinical and commercial impact
Early-stage company structure offers clear visibility into product development and potential for meaningful career progression as the company scales

Watch Out For

Pre-revenue stage with no visible clinical trial activity (0 Phase 1/2/3 programs) raises questions about development timeline and clinical progress
Complete absence of job openings (0 active positions) and lack of disclosed funding information suggest the company may be in stealth mode or early fundraising phase
No published research output and minimal public visibility make it difficult to assess scientific credibility or competitive positioning

Generated by Claude from Ancora Heart's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GDS Accucinch System

Severe Functional Mitral Regurgitation and Heart Failure

N/A

Clinical Trials (1)

NCT02153892Feasibility of the AccuCinch® System for Left Ventricular Reshaping of the Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve Left Ventricular Function

N/A

AccuCinch Ventricular Restoration System

Heart Failure With Reduced Ejection Fraction (HFrEF)

N/A

Clinical Trials (1)

NCT04331769Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

N/A

AccuCinch® Ventricular Restoration System

Heart Failure

N/A

Clinical Trials (1)

NCT03560167Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation

N/A

Accucinch Implant

Heart Failure

N/A

Clinical Trials (1)

NCT02624960Safety and Performance of the AccuCinch® System

N/A

AccuCinch® Ventricular Restoration

Heart Failure

N/A

Clinical Trials (1)

NCT03533517Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction

N/A

Mitral valve repair

Heart Failure

N/A

Clinical Trials (1)

NCT02806570The CorCinch - Functional Mitral Valve Regurgitation (FMR) Study

N/A

AccuCinch® Ventriculoplasty System

Functional Mitral Regurgitation

N/A

Clinical Trials (1)

NCT01899573Percutaneous Left Ventricular Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function

N/A

AccuCinch® Ventriculoplasty System

Mitral Regurgitation

N/A

Clinical Trials (1)

NCT00800046A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2021

Portfolio: 9 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

7 pipeline

Marketed

Pipeline